Not every promising medicine reaches patients — and that is an important part of the drug-development story too. On 24 July 2026, Sanofi announced that it would discontinue clinical development of amlitelimab for moderate-to-severe atopic dermatitis and would not submit the treatment for global regulatory review in atopic dermatitis.
Amlitelimab is an investigational monoclonal antibody targeting OX40 ligand, or OX40L. The OX40/OX40L pathway has attracted considerable scientific interest because of its role in activation and survival of T cells involved in chronic inflammation. Researchers hoped that targeting this pathway might provide a different way to achieve long-lasting disease control. Sanofi's programme progressed through Phase 3 development. The company's ESTUARY long-term extension study showed maintenance of clinical response without relapse in patients aged 12 years and older, according to Sanofi.
Nevertheless, after reviewing the totality of efficacy and safety evidence, Sanofi concluded that amlitelimab would not represent a meaningful enough improvement over the current standard of care to justify continuing the atopic dermatitis programme.
That conclusion captures how dramatically the treatment landscape has changed. A decade ago, proving that a new systemic treatment worked could itself represent a major breakthrough. Today, biologics and JAK inhibitors can produce substantial improvements in many patients. A new medicine therefore needs to compete against treatments that are already effective.
Companies must increasingly ask not only “Does this work?” but “Does it offer enough additional value?”
That value might involve greater skin clearance, stronger itch reduction, faster onset, improved safety, longer treatment intervals or effectiveness in patients who fail other therapies. For patients who had been following amlitelimab research, the decision may be disappointing. But stopping a programme is not necessarily evidence that the science was worthless. Clinical trials generate information about disease mechanisms, treatment targets, safety and outcome measures even when a medicine does not reach the market.
The decision also does not end interest in OX40/OX40L biology. Other researchers continue to investigate related mechanisms in inflammatory diseases. Amlitelimab's story therefore illustrates the increasingly demanding environment surrounding atopic dermatitis drug development.
»The therapeutic bar is rising.«
That is ultimately a positive sign for patients, even when individual programmes fail. Future treatments will increasingly need to demonstrate a clear reason for their existence alongside therapies already available.